Stock Price

The NYSE delisted Lanvin Group's warrants, citing an 'abnormally low price.' This move highlights the exchange's tougher stance and raises questions about the luxury firm.

uniQure's upsized $259M offering signals massive investor confidence, fueling its Huntington's therapy, AMT-130, and reshaping the gene therapy landscape.

With court approval secured, First Capital's $9.4B sale to KingSett and Choice Properties is nearly complete, signaling a major consolidation in Canada's prized grocery-anchored real estate market.

After a blockbuster NYSE debut, a deep dive into how manufacturer Doncasters will use $1B to pay down debt and dominate the high-tech components market.

The high court's 7-2 decision on Roundup not only ends a legal saga for Bayer but signals a major shift in product liability across all federally regulated industries.

Healthcare tech firm Phreesia faces a securities fraud lawsuit alleging it misled investors on growth, casting doubt on its Network Solutions segment.

SUI Group's expanded loan to Bluefin isn't just a deal; it's a strategic maneuver to consolidate Sui's DeFi landscape and forge a new model for institutional investment.

Greenland Mines charts a bold path for its Skaergaard project, but can it navigate the treacherous terrain of Arctic mining and financial instability?

An institutional investor just paid a 25% premium for VCI Global stock. We go beyond the headline to unpack the AI platform that commanded this confidence.

After decades of a fragmented identity, Del Monte consolidates its brand, aiming for growth by bridging the gap between fresh produce and center-aisle goods.

The tech firm is buying back nearly half its shares. We analyze if this massive tender offer is a bold bet on its AI future or a retreat from growth.

A strategic blend of new technology and favorable market conditions breathes new life into a legendary Canadian gold mine, adding millions of ounces.

After an 80% stock collapse, Dye & Durham replaces its CEO. A new 'Transformation Committee' now steers the ship, tasked with restoring discipline and navigating a critical strategic review.

Allegiant Travel Company's successful debt tender isn't just a simple refinance; it's a masterclass in corporate strategy to shed constraints and fuel growth.

Kadima Neuropsychiatry sues NRx Pharma, alleging deceit in a failed acquisition. The case reveals the high stakes of corporate integrity and financial truth.

Long-term shareholder Phoenix Asset Management publicly pressures UK homebuilder Barratt Redrow to accelerate buybacks, citing deep undervaluation.

With its crucial Jet.AI merger vote adjourned to the wire, flyExclusive touts record operations. But can the tech acquisition reverse a 50% stock slide?

Apollo Commercial Real Estate's large dividend has activated a special NYSE rule. We break down what the 'due bill' period means for shareholders and market mechanics.

Facing delisting, Virax Biolabs consolidates its shares in a bid to survive. This move buys time, but the real test lies in its innovative T-cell technology.

Despite passing all resolutions, Novavax faces a reckoning as nearly half of shareholders reject its pay plan, amplifying activist investor Shah Capital's demands.